Faster European drug reviews
Executive Summary
U.K.'s National Institute for Clinical Excellence announces plans to expedite reviews. NHS division is "in discussion with the Department of Health over proposals for a revised process allowing more rapid appraisal of important new drugs." The proposals were evaluated by NICE's board at a meeting Sept. 21. The European Medicines Agency has also proposed its new framework for Scientific Advice & Protocol Assessment, which "provides for earlier and greater involvement of internal assessors and external experts." Comments are due by Nov. 22. EMEA projects the new review procedure could reduce response time from 100 days to 70 days (1"The Pink Sheet" July 11, 2005, p. 26)...
You may also be interested in...
EMEA Working To Substantially Shorten Scientific Advice Response Time
The European Medicines Agency is developing a new scientific advice procedure aimed at shortening the timeframe for providing drug development feedback to manufacturers
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.